"As one of the nation's leading comprehensive cancer centers, M Health Fairview Cancer Care combines a rich history of science and discovery with a commitment to delivering personalized care for each and every family that we serve. From the common to complex, our approach to cancer care starts with understanding you and how to best apply our academic-driven research, multidisciplinary expertise, and innovative approach to personalized care in order to develop a treatment path tailored for you. Our Masonic Cancer Clinic is located on the second floor of the M Health Fairview Clinics and Surgery Center - Minneapolis."

During the past decade, University of Minnesota Cancer Center-Fairview conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Minnesota Cancer Center-Fairview" #1 collaborator was "Children's Oncology Group" with 2 trials as a collaborator and "National Cancer Institute (NCI)" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "University of Minnesota Cancer Center-Fairview" are "Adult Nasal Type Extranodal NK/T-cell Lymphoma" (1 trials), "Anaplastic Large Cell Lymphoma" (1 trials), "Angioimmunoblastic T-cell Lymphoma" (1 trials), "Childhood Burkitt Lymphoma" (1 trials) and "Childhood Diffuse Large Cell Lymphoma" (1 trials). Many other conditions were trialed in "University of Minnesota Cancer Center-Fairview" in a lesser frequency.

Most popular intervention types in "University of Minnesota Cancer Center-Fairview" are "Drug" (2 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Axitinib" (1 trials), "Eribulin Mesylate" (1 trials), "anti-endosialin/TEM1 monoclonal antibody MORAb-004" (1 trials), "laboratory biomarker analysis" (1 trials) and "pharmacological study" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of Minnesota Cancer Center-Fairview" are 3 trials for "All" genders.

Currently, there are NaN active trials in "University of Minnesota Cancer Center-Fairview". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in University of Minnesota Cancer Center-Fairview, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in University of Minnesota Cancer Center-Fairview, 3 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".